|

Tocilizumab Clinical Trials

32 actively recruiting trials across 16 locations

Also known as: ACTEMRA, ACTEMRA®, Actemra, Actemra, RoActemra, Actemra, RoActemra, RO4877533 +3 more

Pipeline

Phase 1: 10Phase 2: 8Phase 3: 4Phase 4: 2Phase 1/2: 8

Top Sponsors

  • Hoffmann-La Roche12
  • Juno Therapeutics, Inc., a Bristol-Myers Squibb Company2
  • University Health Network, Toronto1
  • SCRI Development Innovations, LLC1
  • Regeneron Pharmaceuticals1

Indications

  • Cancer24
  • Arthritis6
  • Multiple Myeloma4
  • Lupus3
  • Systemic Lupus Erythematosus2

Other9 trials

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
Phase 1
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
Phase 2
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Phase 1
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Phase 1/2
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Phase 1
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Phase 3
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Phase 1
Plan Development for Giving Teclistamab in the Outpatient Setting
Phase 4
Use of Tocilizumab Drug Levels to Optimize Treatment in RA
Phase 4

San Francisco, California4 trials

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program

Phase 1
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

University of California, San Francisco

Phase 2
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

University of San Francisco, California

Phase 2
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

University of California San Francisco Pediatric Rheumatology

Phase 3

Birmingham, Alabama2 trials

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Children's Hospital of Alabama

Phase 1/2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

University of Alabama_6th Ave

Phase 1/2

Duarte, California2 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope

Phase 1/2
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

City of Hope National Medical Center

Phase 1/2

Aurora, Colorado2 trials

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

University of Colorado Anschutz Medical Campus

Phase 1
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Children's Hospital Colorado

Phase 2

Atlanta, Georgia2 trials

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Winship Cancer Institute at Emory University

Phase 2
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Emory University

Phase 2

Phoenix, Arizona1 trial

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Phoenix Children's Hospital /ID# 253403

Phase 3

Tucson, Arizona1 trial

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Arizona Oncology Associates

Phase 2

Berkeley, California1 trial

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Alta Bates Summit Medical Center

Phase 3

Costa Mesa, California1 trial

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

UC Irvine Medical Center

Phase 1/2

La Jolla, California1 trial

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

UC San Diego Moores Cancer Center

Phase 1

Harvey, Illinois1 trial

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Ingalls Memorial Hospital

Phase 1/2

Boston, Massachusetts1 trial

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Local Institution - 0041

Phase 1

Rochester, Minnesota1 trial

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Mayo Clinic Rochester

Phase 1

New York, New York1 trial

Neutralizing Interleukin (IL)-6

Icahn School of Medicine at Mount Sinai

Phase 2

Philadelphia, Pennsylvania1 trial

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Abramson Cancer Center of the University of Pennsylvania

Phase 1/2

Pittsburgh, Pennsylvania1 trial

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

Allegheny Health Network Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.